Newron Pharmaceuticals will host its 2024 Investor Day on June 25 in New York City
 

New hope emerges for treatment-resistant schizophrenia: leading KOLs to reveal insights into the neurobiology of treatment for both poorly responding and treatment-resistant patients

Company to lay out the roadmap for US and EU registration for evenamide

Milan, Italy and Morristown, NJ, USA – June 5, 2024 - Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system (CNS), today announced that it will host its 2024 Investor Day on Tuesday, June 25, 2024, in New York City.

This event will be held at Convene, 530 Fifth Avenue (between 44^th and 45^th Streets) in New York City, from 9:00-11:00 AM EDT. Institutional investors, business partners, analysts and media representatives who are interested in attending in person or virtually can register using this link. The Investor Day will also be accessible via live webcast on Newron’s investor website.

Stefan Weber, Chief Executive Officer and Ravi Anand, MD, Chief Medical Officer will host the event, which will focus on the Company’s clinical, scientific and commercial plans for evenamide for chronic and treatment resistant schizophrenia. Three of the world’s leading experts in neuroscience and schizophrenia will join the Company’s management to explore the unmet needs, new concepts and recent neurobiological findings for treating poor responders and patients with treatment-resistant schizophrenia.

Speakers:

Anthony Grace, Ph.D., Distinguished Professor of Neuroscience, Professor of Psychiatry and Psychology University of Pittsburgh will present breakthrough pre-clinical data on treatment resistant schizophrenia:

Evenamide can exert unique efficacy in schizophrenia by targeting the site of pathology: preclinical evidence supports effects seen in patients with TRS

John Kane, M.D., Co-Director & Professor, Institute of Behavioural Science,
Feinstein Institutes for Medical Research, Professor of Psychiatry, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell will address the topic:

Difficult to treat, poorly responding patients with schizophrenia; new, unique results with evenamide offer new hope for these patients

Stephen R. Marder, M.D., Daniel X. Freedman Professor of Psychiatry, Semel Institute of Neuroscience & Human Behavior, Director, Section on Psychosis, UCLA Neuropsychiatric Institute will present:
New Hope for Patients with Treatment-Resistant Schizophrenia; Unique Results with Evenamide, a Glutamate Modulator, as an Add-On Medication

“We are honored to have three of the most distinguished medical researchers in the field of schizophrenia and treatment resistant schizophrenia, such as Anthony Grace, Ph.D., Dr. John Kane and Dr. Stephen Marder, join our discussions in New York,” said Stefan Weber, CEO of Newron. “We look forward to updating the research community, investors and potential partners with our progress on June 25.”

Venue:

Convene
530 Fifth Avenue
(between 44^th and 45^th Streets)
New York City, NY
9:00-11:00 AM EDT
A continental breakfast will be served at 8:30 AM ET
Click here to register to attend in person or virtually

About evenamide
Evenamide, an orally available new chemical entity, specifically blocks voltage-gated sodium channels (VGSCs) and is devoid of biological activity at >130 other CNS targets. It normalizes glutamate release induced by aberrant sodium channel activity (veratridine-stimulated), without affecting basal glutamate levels, due to inhibition of VGSCs. Combinations of ineffective doses of evenamide and other APs, including clozapine, were associated with benefit in animal models of psychosis, suggesting synergies in mechanisms that may provide benefit in patients who are poor responders to current APs, including clozapine.

About Newron Pharmaceuticals                                                                                    
Newron (SIX: NWRN, XETRA: NP5) is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system. The Company is headquartered in Bresso near Milan, Italy. Xadago®/safinamide has received marketing authorization for the treatment of Parkinson’s disease in the European Union, Switzerland, the UK, the USA, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan and South Korea, and is commercialized by Newron’s Partner Zambon. Supernus Pharmaceuticals holds the commercialization rights in the USA. Meiji Seika has the rights to develop and commercialize the compound in Japan and other key Asian territories. Newron is also developing evenamide as the potential first add-on therapy for the treatment of patients with symptoms of schizophrenia. For more information, please visit: www.newron.com

For more information, please contact:

Newron

Stefan Weber
CEO  
+39 02 6103 46 26  
pr@newron.com

UK/Europe

Simon Conway / Ciara Martin / Natalie Garland-Collins
FTI Consulting  
+44 20 3727 1000  
SCnewron@fticonsulting.com

Switzerland

Valentin Handschin
IRF 
+41 43 244 81 54  
handschin@irf-reputation.ch

Germany/Europe

Anne Hennecke / Caroline Bergmann
MC Services  
+49 211 52925222 
newron@mc-services.eu

USA

Paul Sagan
LaVoieHealthScience  
+1 617 374 8800, Ext. 112 
psagan@lavoiehealthscience.com

Important Notices

This document contains forward-looking statements, including (without limitation) about (1) Newron’s ability to develop and expand its business, successfully complete development of its current product candidates, the timing of commencement of various clinical trials and receipt of data and current and future collaborations for the development and commercialization of its product candidates, (2) the market for drugs to treat CNS diseases and pain conditions, (3) Newron’s financial resources, and (4) assumptions underlying any such statements. In some cases, these statements and assumptions can be identified by the fact that they use words such as “will”, “anticipate”, “estimate”, “expect”, “project”, “intend”, “plan”, “believe”, “target”, and other words and terms of similar meaning. All statements, other than historical facts, contained herein regarding Newron's strategy, goals, plans, future financial position, projected revenues and costs and prospects are forward-looking statements. By their very nature, such statements and assumptions involve inherent risks and uncertainties, both general and specific, and risks exist that predictions, forecasts, projections and other outcomes described, assumed or implied therein will not be achieved. Future events and actual results could differ materially from those set out in, contemplated by or underlying the forward-looking statements due to a number of important factors. These factors include (without limitation) (1) uncertainties in the discovery, development or marketing of products, including without limitation difficulties in enrolling clinical trials, negative results of clinical trials or research projects or unexpected side effects, (2) delay or inability in obtaining regulatory approvals or bringing products to market, (3) future market acceptance of products, (4) loss of or inability to obtain adequate protection for intellectual property rights, (5) inability to raise additional funds, (6) success of existing and entry into future collaborations and licensing agreements, (7) litigation, (8) loss of key executive or other employees, (9) adverse publicity and news coverage, and (10) competition, regulatory, legislative and judicial developments or changes in market and/or overall economic conditions. Newron may not actually achieve the plans, intentions or expectations disclosed in forward-looking statements and assumptions underlying any such statements may prove wrong. Investors should therefore not place undue reliance on them. There can be no assurance that actual results of Newron's research programs, development activities, commercialization plans, collaborations and operations will not differ materially from the expectations set out in such forward-looking statements or underlying assumptions. Newron does not undertake any obligation to publicly update or revise forward-looking statements except as may be required by applicable regulations of the SIX Swiss Exchange or the Dusseldorf Stock Exchange where the shares of Newron are listed. This document does not contain or constitute an offer or invitation to purchase or subscribe for any securities of Newron and no part of it shall form the basis of or be relied upon in connection with any contract or commitment whatsoever.